The Promise of Prediction Markets

Prediction markets are markets for contracts that yield payments based on the outcome of an uncertain future event, such as a presidential election. Using these markets as forecasting tools could substantially improve decision making in the private and public sectors. We argue that U.S. regulators should lower barriers to the creation and design of prediction markets by creating a safe harbor for certain types of small stakes markets. We believe our proposed change has the potential to stimulate innovation in the design and use of prediction markets throughout the economy, and in the process to provide information that will benefit the private sector and government alike.Technology and Industry

Blueberry Progress Reports

The 1979 edition of the Blueberry Progress Reports was prepared for the Maine Blueberry Commission and the University of Maine Blueberry Advisory Committee by researchers with the Maine Life Sciences and Agriculture Experiment Station and Maine Cooperative Extension Service at the University of Maine, Orono. Projects in this report include: 1. Cooperative Extension Activities 2. Plan of Work - FY 1980 3. Weed Control in Lowbush Blueberry Fields 4. Pruning of Blueberries 5. Integrated Management of Blueberry Fields 6. Physiology and Culture of the Lowbush Blueberry 7. Effect of Plant-Water Stress on Lowbush Blueberry Growth, Yield and Quality 8. Blueberry Pathology 9. Botrytis Blossom Blight of Lowbush Blueberries 10. Insects Affecting the Blueberr

Phase II Trial of Concurrent Sunitinib and Image-Guided Radiotherapy for Oligometastases

BACKGROUND: Preclinical data suggest that sunitinib enhances the efficacy of radiotherapy. We tested the combination of sunitinib and hypofractionated image-guided radiotherapy (IGRT) in a cohort of patients with historically incurable distant metastases. METHODS: Twenty five patients with oligometastases, defined as 1-5 sites of active disease on whole body imaging, were enrolled in a phase II trial from 2/08 to 9/10. The most common tumor types treated were head and neck, liver, lung, kidney and prostate cancers. Patients were treated with the recommended phase II dose of 37.5 mg daily sunitinib (days 1-28) and IGRT 50 Gy (days 8-12 and 15-19). Maintenance sunitinib was used in 33% of patients. Median follow up was 17.5 months (range, 0.7 to 37.4 months). RESULTS: The 18-month local control, distant control, progression-free survival (PFS) and overall survival (OS) were 75%, 52%, 56% and 71%, respectively. At last follow-up, 11 (44%) patients were alive without evidence of disease, 7 (28%) were alive with distant metastases, 3 (12%) were dead from distant metastases, 3 (12%) were dead from comorbid illness, and 1 (4%) was dead from treatment-related toxicities. The incidence of acute grade ≥ 3 toxicities was 28%, most commonly myelosuppression, bleeding and abnormal liver function tests. CONCLUSIONS: Concurrent sunitinib and IGRT achieves major clinical responses in a subset of patients with oligometastases. TRIAL REGISTRATION: ClinicalTrials.gov NCT00463060

Targeting the Lactate Transporter MCT1 in Endothelial Cells Inhibits Lactate-Induced HIF-1 Activation and Tumor Angiogenesis

Switching to a glycolytic metabolism is a rapid adaptation of tumor cells to hypoxia. Although this metabolic conversion may primarily represent a rescue pathway to meet the bioenergetic and biosynthetic demands of proliferating tumor cells, it also creates a gradient of lactate that mirrors the gradient of oxygen in tumors. More than a metabolic waste, the lactate anion is known to participate to cancer aggressiveness, in part through activation of the hypoxia-inducible factor-1 (HIF-1) pathway in tumor cells. Whether lactate may also directly favor HIF-1 activation in endothelial cells (ECs) thereby offering a new druggable option to block angiogenesis is however an unanswered question. In this study, we therefore focused on the role in ECs of monocarboxylate transporter 1 (MCT1) that we previously identified to be the main facilitator of lactate uptake in cancer cells. We found that blockade of lactate influx into ECs led to inhibition of HIF-1-dependent angiogenesis. Our demonstration is based on the unprecedented characterization of lactate-induced HIF-1 activation in normoxic ECs and the consecutive increase in vascular endothelial growth factor receptor 2 (VEGFR2) and basic fibroblast growth factor (bFGF) expression. Furthermore, using a variety of functional assays including endothelial cell migration and tubulogenesis together with in vivo imaging of tumor angiogenesis through intravital microscopy and immunohistochemistry, we documented that MCT1 blockers could act as bona fide HIF-1 inhibitors leading to anti-angiogenic effects. Together with the previous demonstration of MCT1 being a key regulator of lactate exchange between tumor cells, the current study identifies MCT1 inhibition as a therapeutic modality combining antimetabolic and anti-angiogenic activities

Laboratory testing of a growth hypothesis for juvenile squid Loligo pealeii (Cephalopoda: Loliginidae)

Growth modeling in squid has been hampered by a paucity of raw growth data on live individuals. We reared wild juvenile squid Loligo pealeii, for up to 97 days post capture, to determine the form of growth and to test the hypothesis that a 5°C difference in temperature would significantly affect growth rates. Precapture growth rates (the instantaneous relative growth rate or percent increase in body mass per day (IRGR)) of 8-11% were estimated using statolith age data. Laboratory growth rates over a maximum of 97 experimental days fell into two phases in which most L. pealeii grew exponentially, albeit at a slower rate in phase 2. In both phases, the values of IRGR were significantly higher for L. pealeii reared at 20°C than for those reared at 15°C, being respectively, 4.36 and 2.69 in phase 1 and 2.57 and 1.63 in phase 2. This study provides strong evidence of phase-specific temperature sensitivity in squid growth. The IRGR values obtained were used to simulate the growth of squid hatched in nature from May to September in a simple predictive model. The growth simulations indicated that, by the end of phase-1 growth, squid hatched in June and July were two and three times the weight, respectively, at the same age, as squid hatched in May, owing to their exposure to warmer temperatures

Trials for Oligometastatic Disease.

<p>Abbreviations: LC, local control; DC, distant control; PFS, progression-free survival; OS, overall survival; fx, fractions; NR = not reported.</p

Adverse Events.

*<p>One case occurred after sunitinib treatment and was likely related to reirradiation performed prior to protocol therapy.</p